Apellis Pharmaceuticals (APLS) - שולי רווח תפעולי

לוגו של חברה ציבורית Apellis Pharmaceuticals, Inc. (APLS)

Apellis Pharmaceuticals (APLS) leads the ophthalmology and rare disease therapy segment, as evidenced by its historical operating margin. The value 15.00 serves as the baseline parameter. Growing Syfovre sales are generating a powerful cash flow, while the diversification of platforms for systemic diseases minimizes risks. Protected patents guarantee the relevance of its solutions, ensuring sustainable business growth.

Apellis Pharmaceuticals, Inc. (APLS): רווחיות הפעילות התפעולית מ-04.07.2022 עד 30.05.2026

Apellis Pharmaceuticals (APLS) - פילוחי מדדים ודוחות פיננסיים

- מחיר ותחזית קונצנזוס למחירים:
הערכת שווי פונדמנטלית של החברה:Apellis Pharmaceuticals, Inc., APLS
מוצר עיקרי של Apellis Corp

To protect capital from inflationary risks, it is critical for investors to monitor the operating margin, which measures the share of profit from core operations before accounting for debt and tax obligations. Analyzing the core operating margin allows for an assessment of cost management efficiency at Apellis Pharmaceuticals (APLS), whose non-cyclical nature within the ophthalmology drug segment ensures high profitability resilience against macroeconomic shocks.